Autopsy report · NCT04501952

Study to Evaluate the Efficacy and Safety of Remdesivir (GS-5734™) Treatment of Coronavirus Disease 2019 (COVID-19) in an Outpatient Setting

“The study was terminated due to study enrollment feasibility and changing needs of non-hospitalized participants. This decision is not based on efficacy or safety concerns.”

The sponsor’s own words in the registry.

Life of this trial

• Registered 1 month before it started.
• Ran for about 8 months before it stopped.
• 584 participants enrolled.
• Results were posted on the registry 6 months after it ended.

Vital statistics

Status

Terminated

Phase

Phase 3

Sponsor

Gilead Sciences

Sponsor type

Industry

Conditions

COVID-19

Interventions

RDV; Placebo to Match RDV

Participants

584

Sites

104

Countries

Denmark, Spain, United Kingdom, United States

Trials that died the same way

• Surgical Treatment of Chronic Neuropathic Pain
  “The study was terminated due to lower than expected enrollment. The decision to terminate the study was not based on any safety or efficacy concerns.” (87% match in meaning)
• Alvimopan Use in Polytraumatized Patients
  “This study was terminated due to failure to enroll, a low volume of patients met criteria.” (86% match in meaning)
• An Open-Label, Randomized, Multicenter Trial of Encorafenib + Binimetinib Evaluating a Standard-dose and a High-dose Regimen in Patients With BRAFV600-mutant Melanoma Brain Metastasis
  “Study terminated due to lack of enrollment of the target population. There were no safety, efficacy, or regulatory interaction involved in the decision to stop enrollment.” (85% match in meaning)
• Evaluation of the Clinical and Economic Impact of painPRIMER in the Treatment of Low Back Pain in a Primary Care Setting
  “The study was terminated on 02-Jun-2014 due to slow enrollment. The study was not terminated for reasons of either safety or efficacy.” (85% match in meaning)
• Treatment Resistance Following Anti-cancer Therapies
  “Study terminated due to lack of enrollment that has been compounded by the global COVID-19 pandemic. There were no safety and/or efficacy concerns involved in the decision to stop enrollment.” (84% match in meaning)

Look deeper

• The official registry record (the source of truth)
• Record history: every change the sponsor made
• Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.